APPENDICURE

Research Spotlight  |  March 2026  |  Appendicure Education Team

If you or a loved one is living with high-grade appendiceal cancer – including high-grade signet ring cell carcinoma – your oncologist may have mentioned specific mutations found in your tumor. Two of the most relevant are KRAS and PIK3CA. A newly published laboratory study offers an important insight: when these two mutations occur together, they appear to make cancer cells significantly more unstable and aggressive than either mutation does on its own.

This research was done in laboratory cells, not yet in patients , but it begins to explain something clinicians have long observed: that some appendiceal tumors behave far more aggressively than their classification alone would suggest.

Starting with KRAS: The Most Common Driver in Appendiceal Cancer

KRAS is the most frequently mutated gene in high-grade Mucinous Adenocarcinoma, including in high-grade signet ring cell tumors. It works like a stuck “on” switch – normally, KRAS only activates when the cell receives a growth signal, then turns off again. When KRAS is mutated, it stays permanently switched on, continuously telling the cell to grow and divide.

The new study confirmed that KRAS mutation alone does cause some internal cellular stress — but notably less than researchers might have expected. Cells with KRAS mutations showed only modest increases in harmful activity compared to normal cells.

So if KRAS is the primary driver in most appendiceal cancers, what explains the wide variation in how aggressive these tumors can be? The researchers found a compelling answer in a second mutation: PIK3CA.

Key concept: What is a signaling ‘pathway’? Think of cell signaling pathways as relay races. A signal starts at the surface of a cell and gets passed from one protein to the next, like runners passing a baton, until it reaches the cell’s control center and triggers a response — “grow,” “divide,” or “make more proteins.” When a gene like KRAS or PIK3CA is mutated, it’s like a runner who never stops passing the baton — the signal keeps going whether the cell needs it or not.

Enter PIK3CA: The Second Mutation That Changes Everything

PIK3CA is the gene that encodes a key protein in the PI3K-AKT signaling pathway – a separate growth-control system that runs alongside the KRAS pathway. PIK3CA mutations are among the most common in cancer overall, and they occur alongside KRAS mutations with notable frequency in colorectal and appendiceal adenocarcinoma.

Here is what the study found that matters most for our community: when KRAS and PI3K pathway activation were combined in laboratory cells, the result was dramatically more cellular chaos than KRAS alone. The cells produced a flood of genetic material (RNA) faster than the cell’s DNA copying machinery could handle. This created a state called replication stress – errors piling up, DNA becoming unstable, the cell lurching forward in an uncontrolled way.

The researchers also confirmed this pattern in real cancer data. Looking at colorectal adenocarcinoma cases in a large national database (TCGA), tumors with both KRAS and PIK3CA mutations showed higher markers of replication stress and genomic instability than tumors with KRAS mutation alone. The same pattern held for BRAF combined with PIK3CA.

Key concept: What is replication stress? Every time a cell divides, it has to make an exact copy of its entire DNA — all six billion letters of it. When cancer-driving mutations force cells to divide too fast or produce too much genetic material at once, the copying machinery gets overwhelmed, like trying to photocopy a book while someone keeps adding more pages. Errors accumulate, the DNA breaks in places, and the cell becomes increasingly unstable. This instability is a hallmark of more aggressive cancers and can also make them harder to treat.

What This Means for You

This is laboratory research – not yet a change in clinical practice. But it has real implications for patients and caregivers navigating appendiceal cancer today:

• Your full mutation profile matters. Knowing whether your tumor carries a PIK3CA mutation in addition to KRAS or BRAF may help explain your tumor’s behavior and could become relevant to treatment decisions as PI3K-targeted therapies continue to develop.
• Co-mutations may amplify aggressiveness. The study suggests that two mutations together can create a cellular environment that is substantially more unstable than either alone. This could help explain why some KRAS-mutant appendiceal tumors behave more aggressively than others.
• PI3K-targeted drugs exist and are being studied. Several PI3K and AKT inhibitors are already in clinical use or trials for other cancer types. This research adds scientific rationale for exploring whether those drugs could be relevant in appendiceal cancer with PI3K pathway mutations.
• Replication stress as a target. The cellular chaos created by these co-mutations — replication stress — is itself a potential vulnerability. Researchers are actively developing drugs that exploit this instability to selectively kill cancer cells. Appendiceal tumors with high replication stress may one day be candidates for this approach.

Questions to Ask Your Oncologist (Bring this list to your next appointment): Has my tumor been tested with comprehensive genomic profiling (such as FoundationOne, Tempus, or Caris)? If so, does my report show a PIK3CA or other PI3K pathway mutation? If I have both a KRAS and a PIK3CA mutation, does that change how you’re thinking about my treatment options? Are there clinical trials targeting the PI3K-AKT pathway, replication stress, or co-mutated KRAS/PIK3CA tumors that I might be eligible for? Would it be worth sending my tumor tissue to a center like MD Anderson, MSK, or UC San Diego Moores for a second opinion on my molecular profile and treatment options?

Glossary of Terms

KRAS

A gene that acts as a growth “on switch” in cells. Mutations in KRAS are the most common driver in appendiceal adenocarcinoma, including high-grade signet ring cell carcinoma. A mutated KRAS gets stuck permanently on, pushing cells to keep dividing.

PIK3CA

The gene encoding the PI3K protein – a key player in a separate growth-control pathway. PIK3CA mutations occur alongside KRAS mutations in a meaningful proportion of appendiceal and colorectal cancers, and the combination appears to significantly amplify cellular instability.

PI3K-AKT Pathway

A signaling chain that runs alongside the RAS-MAPK pathway and controls cell growth, survival, and the production of proteins. When both pathways are simultaneously activated by co-mutations, the effect on cellular chaos is greater than either alone.

Replication Stress

What happens when cancer cells are forced to copy their DNA too fast or under too much internal pressure. The copying machinery makes errors, DNA breaks accumulate, and the cell becomes genetically unstable — a feature of more aggressive tumors.

Hypertranscription

When a cancer cell produces far more RNA (the molecular instructions used to make proteins) than a normal cell, flooding its own systems and contributing to replication stress.

Co-Mutation

When two or more distinct gene mutations are present in the same tumor. Co-mutations in KRAS and PIK3CA are not rare in appendiceal cancer and may have meaningful effects on tumor behavior.

Comprehensive Genomic Profiling (CGP)

Advanced tumor testing that analyzes many genes at once – typically from a tissue sample or blood draw – to identify mutations that may affect prognosis, treatment selection, or clinical trial eligibility.

Looking Ahead

Research like this is exactly why knowing your full molecular profile matters – not just your cancer type, but the specific genetic alterations driving it. As PI3K-targeted therapies continue to advance, and as replication stress becomes an increasingly recognized therapeutic target, appendiceal cancer patients with co-mutations may find themselves at the center of a critical new chapter in treatment development.

Appendicure is committed to staying at the frontier of this science and bringing it to you in language that is useful, honest, and actionable. If you have questions about your pathology report, your mutation profile, or clinical trials, reach out to us. You don’t have to navigate this alone.

Source: Kelly et al., “PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress,” bioRxiv preprint, March 2026. This post is for patient education only and does not constitute medical advice. Please consult your oncology team before making any treatment decisions.